期刊文献+

研制高效疟疾疫苗的几个关键技术问题

Key technological issues in developing effective malaria vaccines
原文传递
导出
摘要 疟疾在很多国家仍然是严重的公共卫生问题,有效的疟疾疫苗将是控制乃至在全球消除疟疾的有效手段之一。抗原的免疫原性、变异性和质量是影响疟疾疫苗成功研制的关键因素,而建立有效的疟疾疫苗功能检测方法是发掘具有潜力的候选抗原的基础。该文综述了这几方面工作的研究结果。 Malaria remains a serious public health problem in many countries. An effective malaria vaccine will be one of the powerful tools to control or even eliminate the disease in the world. Several factors, such as immunogenicity, variation and quality of malaria antigens, are significant influences on the development of successful malaria vaccines. Besides, it is essential and imperative to establish efficient functional assays of malaria vaccines for the discovery of those antigen candidates with the most potential. The efforts made in these aspects are covered in this article.
作者 钱锋
出处 《国际医学寄生虫病杂志》 CAS 2014年第1期1-5,56,共6页 International JOurnal of Medical Parasitic Diseases
关键词 疟疾 疫苗 研制 Malaria Vaccine Development
  • 相关文献

参考文献42

  • 1RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children[J].{H}New England Journal of Medicine,2011,(20):1863-1875.
  • 2Ogutu BR,Apollo OJ,McKinney D. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya[J].PLoS One,2009,(03):e4708.
  • 3Eisenbarth SC,Colegio OR,O'Connor W. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants[J].{H}NATURE,2008,(7198):1122-1126.
  • 4Mullen GE,Ellis RD,Miura K. Phase 1 trial of AMA1-C1/ Alhydrogel plus CPG 7909:an asexual blood-stage vaccine for Plas modium falcip arum malaria[J].PLoS One,2008,(08):e2940.
  • 5Ellis RD,Martin LB,Shaffer D. Phase 1 trial of the Plasmodiumfalciparum blood stage vaccine MSP1 (42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults[J].PLoS One,2010,(01):e8787.
  • 6Bargieri DY,Rosa DS,Braga C J. New malaria vaccine candidates based on the Plasmodium vivax merozoite surface protein1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin[J].{H}VACCINE,2008,(48):6132-6142.
  • 7Bargieri DY,Leite JA,Lopes SC. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella Typhimurium[J].{H}VACCINE,2010,(16):2818-2826.
  • 8Wu Y,Przysiecki C,Flanagan E. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex[J].{H}Proceedings of the National Academy of Sciences(USA),2006,(48):18243-18248.doi:10.1073/pnas.0608545103.
  • 9钱锋,徐沪济.疟疾偶联疫苗[J].中国寄生虫学与寄生虫病杂志,2012,30(5):393-395. 被引量:6
  • 10Yoshida S,Araki H,Yokomine T. Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice[J].{H}Infection and Immunity,2010,(02):595-602.

二级参考文献24

  • 1Thiem VD, Lin FY, Canh do G, et al. The Vi conjugate iyphoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines[J]. Clin Vaccine Immunol, 2011, 18(5): 730-735.
  • 2Torafio G, Toledo ME, Baly A, et al. Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Haertu- philus influenzae type b in human adult volunteers [J]. Clin Vac- cine Immunol, 2006, 13(9): 1052-1056.
  • 3Br-ker M, Dull PM, Rappuoli R, et al. Chemistry of a new investiga- tional quadrivalent meningococcal conjugate vaccine that is im- munogenic at all ages [J]. Vaccine, 2009, 27(41): 5574-5580.
  • 4Poolman J, Frasch C, Nurkka A, et al. Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines [J]. Clin Vac- cine Immunol- 2011, 18(2): 327-336.
  • 5Fass R, van de Walle M, Shiloach A, et al. Use of high densi- ty cultures of Escherichia coli for high level production of re- combinant Pseudomonas aeruginosa exotoxin A [J]. Appl Micro- biol Biotechnol, 1991, 36(1): 65-69.
  • 6Giannini G, Rappuoli R, Ratti G. The amino-acid sequence of two non-toxic mutants of diphtheria toxirr CRM45 and CRM197 [J]. Nu- cleic Acids Res, 1984, 12(10): 4063-4069.
  • 7Tsai CM, Frasch CE, Mocca LF. Five structural classes of major outer membrane proteins in Neisseria meningitidis [J]. J Bacteri-ol, 1981, 146(1): 69-78.
  • 8Pastan I, FitzGerald D. Pseudomonas exotoxin: chimeric toxins [J]. J Biol Chem, 1989, 264 (26): 15157-15160.
  • 9Fu J, Bailey FJ, King JJ, et al. Recent advances in the large scale fermentation of Neisseria meningitidis group B for the pro- duction of an outer membrane protein complex [J]. Nat Biotech- nol, 1995, 13(2): 170-174.
  • 10Qian F, Wu Y, Muratova O, et al. Conjugating recombinant pro- teins to Pseudomonas aeruginosa exoprotein A: a strategy for en- hancing immunogenicity of malaria vaccine candidates [J]. Vaccine, 2007, 25(20): 3923-3933.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部